Article
Oncology
Zhenxing Lu, Yintong Teng, Xiaodong Ning, Hao Wang, Weijing Feng, Caiwen Ou
Summary: This study found that among patients with stage I and stage II classic Hodgkin lymphoma (cHL), the risk of cardiovascular disease (CVD) mortality exceeded that of cHL mortality over time, with CVD becoming the leading cause of death.
Article
Oncology
Chiara Gerardi, Eleonora Allocati, Carla Minoia, Attilio Guarini, Rita Banzi
Summary: The research team aimed to summarize evidence on late sequelae after treatment of classical Hodgkin lymphoma and diffuse large B cell lymphoma in long-term survivors, finding that follow-up mainly focused on solid tumors with scant evidence on hematological malignancies.
Article
Oncology
Agnes Dumas, Karen Milcent, Nicolas Bougas, Daniel Bejarano-Quisoboni, Chiraz El Fayech, Helene Charreire, Odile Oberlin, Catherine Patte, Julie Allard, Eric Thebault, Amel Boumaraf, Amel Belhout, Vu-Bezin Giao, Vincent Souchard, Angela Jackson, Rodrigue Allodji, Dominique Valteau-Couanet, Christelle Dufour, Gilles Vassal, Nadia Haddy, Florent De Vathaire, Brice Fresneau
Summary: The study found that patients who received combined chemotherapy and radiotherapy, had bone sarcoma, central nervous system primitive tumor, or underwent autologous hematopoietic cell transplant were more likely to attend long-term follow-up visits. Additionally, factors such as health status, medical expenses, social status, and distance from the follow-up center also influenced attendance.
Article
Oncology
Matthew W. Parsons, Calvin Rock, Jonathan J. Chipman, Harsh R. Shah, Boyu Hu, Deborah M. Stephens, Randa Tao, Jonathan D. Tward, David K. Gaffney
Summary: Non-Hodgkin lymphoma survivors have an increased risk of secondary malignancies, with chemotherapy being associated with higher risk and radiotherapy not increasing overall risk. The risk of secondary malignancies varies among different racial groups and treatment modalities.
Article
Oncology
Matthew R. LeBlanc, Sheryl Zimmerman, Thomas W. LeBlanc, Ashley Leak Bryant, Kathryn E. Hudson, Sophia K. Smith
Summary: This study found that one in three NHL survivors experience clinically meaningful fatigue long after their diagnosis and initial treatment, with approximately 18.7% still reporting persistent fatigue at five years. Factors independently associated with persistent fatigue included female gender, less education, past chemotherapy, increased comorbidities, and posttraumatic stress symptoms.
LEUKEMIA & LYMPHOMA
(2022)
Article
Oncology
Matjaz Popit, Marjan Zaletel, Bojana Zvan, Lorna Zadravec Zaletel
Summary: This study investigated the long-term effects of therapeutic modalities on arterial stiffness and flow-mediated dilation in Hodgkin lymphoma patients. The results showed increased arterial stiffness and no change in flow-mediated dilation in these patients. Neck radiotherapy increased arterial stiffness while anthracyclines decreased it. The study suggests that Hodgkin lymphoma patients may be at increased risk of stroke and should be monitored for carotid disease.
Review
Oncology
Beatriz Nunez-Garcia, Marta Rodriguez-Pertierra, Silvia Sequero, Laura G. Carvajal, Alberto Ruano-Ravina, David Aguiar, Josep Guma, Cristina Q. Blanco, Francisco R. Garcia Arroyo, Yago Garitaonaindia, Zaida Provencio, Virginia Calvo, Carmen Gonzalez-San Segundo, Mariano Provencio
Summary: Nodular lymphocytic predominance Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma with unique characteristics. The study found that patients had a good prognosis but there was a risk of tumor relapse, and treatment plans could be adjusted to reduce toxicity.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Pediatrics
Melissa M. Hudson, Smita Bhatia, Jacqueline Casillas, Wendy Landier
Summary: Advancements in cancer therapy have improved survival rates for children, adolescents, and young adults with cancer, but they are still at risk for long-term therapy-related complications. Therefore, ongoing systematic follow-up and health counseling are crucial to early detection and intervention for potential late-onset complications, as well as promoting healthy lifestyles to reduce risks for common adult health problems. Healthcare providers play a key role in the ongoing care of childhood cancer survivors, beyond routine preventive care, health supervision, and guidance.
Editorial Material
Hematology
Nancy L. Bartlett
Summary: The study discusses a 10-year follow-up of a Children's Oncology Group trial for intermediate-risk Hodgkin lymphoma, highlighting the challenging task of optimizing treatment for this disease.
Article
Oncology
Matthew S. Davids, Andrew W. Roberts, Vaishalee P. Kenkre, William G. Wierda, Abhijeet Kumar, Thomas J. Kipps, Michelle Boyer, Ahmed Hamed Salem, John C. Pesko, Jennifer A. Arzt, Margaret Mantas, Su Y. Kim, John F. Seymour
Summary: In this study, all patients received venetoclax monotherapy at doses of 200 to 1200 mg daily and were evaluated for ORR, PFS, DoR, and AEs. Venetoclax monotherapy was found to have a manageable safety profile and achieve durable responses in a subset of patients with FL, MCL, WM, and MZL, particularly in those who achieved CR. Further research is needed to explore combination strategies to enhance the durability of response to venetoclax.
CLINICAL CANCER RESEARCH
(2021)
Review
Pediatrics
Maria Otth, Johanna Wyss, Katrin Scheinemann
Summary: This review provides a global overview of the potential late effects and long-term follow-up care for survivors of pediatric central nervous system tumors. It emphasizes the importance of cognitive and psychosocial effects, as well as the potential risks of endocrine, metabolic, cardiovascular, and cerebrovascular diseases in CNS tumor survivors.
Article
Oncology
Manya Jerina Hendriks, Erika Harju, Gisela Michel
Summary: Research suggests that childhood cancer survivors have unmet needs in terms of lacking psychosocial support, collaboration in care, starting from scratch, and the demand for centralized, specialized, and individualized services. There is a strong need for integrating psychosocial support in long-term follow-up care and providing personalized, centralized, and interdisciplinary care for all childhood cancer survivors.
Article
Oncology
Beatriz Nunez-Garcia, Mariola Blanco Clemente, Juan Cristobal Sanchez, Ana Royuela, Blanca Cantos Sanchez de Ibarguen, Miriam Mendez, Jorge V. Lopez-Ibor, Marta Martinez, Cristina Traseira, Yago Garitaonaindia, Ramon Aguado, Virginia Calvo, Maria Torrente, Consuelo Parejo, Zaida Provencio, Mariano Provencio
Summary: The high cure rates of Hodgkin lymphoma (HL) make it one of the diseases with the greatest number of long-term survivors. A single-institution study shows that although there has been therapeutic optimization, deaths from cardiovascular disease and second malignant neoplasms (SMNs) continue to occur in HL patients. Monitoring of risk factors, development of prevention programs, and further investigation into the therapeutic optimization of HL are necessary.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Andrea Izquierdo, Diana Mojon, Alfredo Bardaji, Anna Carrasquer, Alicia Calvo-Fernandez, Jose Carreras-Mora, Teresa Giralt, Silvia Perez-Fernandez, Nuria Farre, Cristina Soler, Claudia Sola-Richarte, Paula Cabero, Beatriz Vaquerizo, Jaume Marrugat, Nuria Ribas
Summary: Myocardial injury in COVID-19 survivors is associated with poor clinical prognosis at one year, independent of age and sex, but not with echocardiographic functional abnormalities at six months.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Hematology
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz
Summary: This study demonstrates that Pembrolizumab provides durable antitumor activity in patients with relapsed or refractory classical Hodgkin lymphoma, and a second course of treatment can reinduce sustained responses after relapse from initial complete response.
Article
Oncology
Derek S. Tsang, Laurence Kim, Zhihui Amy Liu, Laura Janzen, Mohammad Khandwala, Eric Bouffet, Normand Laperriere, Hitesh Dama, Dana Keilty, Tim Craig, Vijay Ramaswamy, David C. Hodgson, Donald Mabbott
Summary: The study evaluated the impact of radiation dose on intellectual function in children with brain tumors. Results showed that dosimetry to specific brain regions was associated with declines in intellectual outcomes, highlighting the importance of careful planning of radiation therapy.
Article
Oncology
Rahul R. Parikh, Kara M. Kelly, David C. Hodgson, Bradford S. Hoppe, Kathleen M. McCarten, Katie Karolczuk, Qinglin Pei, Yue Wu, Steve Y. Cho, Cindy Schwartz, Peter D. Cole, Kenneth Roberts
Summary: In the treatment of high-risk cHL patients, most relapses occur in non-bulky initial sites, mainly due to response-adapted radiation therapy given to patients with bulky disease. This study found low rates of failures outside of the personalized radiation treatment volumes, and FDG uptake on PET2 did not accurately identify most relapse sites.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
Sumit Gupta, Rinku Sutradhar, Sarah Alexander, Michelle Science, Cindy Lau, Chenthila Nagamuthu, Mohammad Agha, Paul C. Nathan, David Hodgson
Summary: Survivors of childhood, adolescent, and young adult cancer do not have an increased risk of COVID-19 infection or severe complications.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Letter
Oncology
Sumit Gupta, Paul C. Nathan, David Hodgson
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Angie Mae Rodday, Susan K. K. Parsons, Jenica N. N. Upshaw, Jonathan W. W. Friedberg, Andrea Gallamini, Eliza Hawkes, David Hodgson, Peter Johnson, Brian K. K. Link, Eric Mou, Kerry J. J. Savage, Pier Luigi Zinzani, Matthew Maurer, Andrew M. M. Evens
Summary: A modern clinical prediction model was developed and validated to improve the prediction of prognosis in patients with advanced-stage classical Hodgkin lymphoma. The model was developed using data from eight international clinical trials and validated using data from real-world registries. Several important predictor variables were identified and an online calculator was created for individualized prediction.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Hematology
Sarah A. A. Milgrom, Jihyun Kim, Qinglin Pei, Inki Lee, Bradford S. S. Hoppe, Yue Wu, David Hodgson, Sandy Kessel, Kathleen M. M. McCarten, Kenneth Roberts, Andrea C. C. Lo, Peter D. D. Cole, Kara M. M. Kelly, Steve Y. Y. Cho
Summary: The Children's Oncology Group AHOD0831 study found that in high-risk Hodgkin lymphoma, using a positron emission tomography (PET) response-adapted approach, slow early responders (SERs) received more intensive therapy than rapid early responders (RERs). Furthermore, baseline PET-based characteristics may improve risk stratification. The study results showed that for RERs, low baseline total lesion glycolysis (TLG) was associated with good event-free survival (EFS), while high baseline TLG was associated with poor EFS. Therefore, patients with a high upfront tumor burden may benefit from intensified therapy, even if they achieve RER status.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Angela Punnett, Nancy N. N. Baxter, David Hodgson, Rinku Sutradhar, Jason D. D. Pole, Cindy Lau, Paul C. C. Nathan, Sumit Gupta
Summary: We used population-based clinical and healthcare data to study the treatment patterns and long-term outcomes of adolescents and young adults (AYA) with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). We collected detailed clinical data of AYA aged 15-21 years at diagnosis with NLPHL in Ontario, Canada between 1992 and 2012. Additional events such as subsequent malignant neoplasms, relapses, and deaths were identified through linkage to healthcare databases. The study found that AYA with NLPHL have excellent long-term survival rates, and resection alone was associated with good outcomes, but strategies to avoid chemotherapy and radiation should be considered due to the risk of subsequent malignant neoplasms.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Inna Y. Y. Gong, Mahmood Aminilari, Ivan Landego, Katrina Hueniken, Qianghua Zhou, John Kuruvilla, David C. C. Hodgson
Summary: The optimal salvage chemotherapy regimen and the efficacy of chimeric antigen receptor T cell (CAR-T) therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) remain uncertain. A network meta-analysis showed that rituximab with gemcitabine, dexamethasone, cisplatin (R-GDP) improved overall survival (OS) and progression-free survival (PFS) compared to other salvage chemotherapy regimens. Another analysis of CAR-T trials demonstrated that both axi-cel and liso-cel improved PFS compared to standard-of-care, with no difference in OS. These findings suggest that R-GDP may be preferred for relapsed/refractory DLBCL, but longer follow-up and comparative survival analysis of CAR-T data are needed to confirm these results.
LEUKEMIA & LYMPHOMA
(2023)
Review
Oncology
Matthew J. Ehrhardt, Jamie E. Flerlage, Saro H. Armenian, Sharon M. Castellino, David C. Hodgson, Melissa M. Hudson
Summary: The successful integration of clinical trials has improved the 5-year survival rate for children with HL, but long-term survivors face late-occurring adverse health effects and increased risk of nonrelapse mortality. Developing treatments to minimize late toxicity is crucial, and there is a need to integrate considerations from frontline treatment and survivorship guidelines into practical documents. Understanding treatment efficacy, toxicity, convenience, and late effects is important for appropriate frontline treatment selection.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Review
Oncology
Scott C. Adams, Jennifer Herman, Iliana C. Lega, Laura Mitchell, David Hodgson, Kim Edelstein, Lois B. Travis, Catherine M. Sabiston, Paaladinesh Thavendiranathan, Abha A. Gupta
Summary: Many survivors of adolescent and young adult cancers face long-term risks of late effects, but evidence-based guidelines for this group have not been developed. A symposium aimed at AYA stakeholders served as a starting point to address this issue and highlighted knowledge gaps for future research.
JNCI CANCER SPECTRUM
(2021)
Article
Oncology
Toma S. Omofoye, Anganile Kalinga, Ramapriya Ganti, Frank J. Minja, Timothy B. Rooney
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Prarthna V. Bhardwaj, Renuka Dulala, Senthil Rajappa, Chandravathi Loke
Summary: The management of breast cancers in India needs greater emphasis on awareness, early detection, standard pathologic testing, and cost-effective solutions. With standardized management, outcomes similar to those of developed countries can be expected. Additionally, clinical trials aimed at a more diverse population in LMICs like India should be undertaken.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Victoria E. Forbes, Mary D. Chamberlin, Vincent Dusabejambo, Tim Walker, Steve P. Bensen, Norrisa Haynes, Kathryn Nunes, Veauthyelau Saint-Joy, Frederick L. Makrauer
Summary: Global health education needs to adapt to the challenges we face, such as inequities and pandemics. Virtual teaching models are effective in delivering global health education and improving outcomes through bidirectional learning and equitable partnerships.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Tefta Isufaj Haliti, Ilir Hoxha, Rubena Mojsiu, Rohini Mandal, Goksu Goc, Kreshnike Dedushi Hoti
Summary: The IOTA Simple Rules have high diagnostic performance in distinguishing between benign and malignant adnexal masses, providing a reliable tool for early diagnosis of ovarian cancer.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Cecilia Felix Penido Mendes de Sousa, Jared Pasetsky, Gustavo Nader Marta, Megan Kassick, Fabio Ynoe Moraes, Luqman K. Dad
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary D. Chamberlin, Dafina Ademi Islami, Shqiptar Demaci, Richard J. Barth Jr
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Jeta Bunjaku, Arber Lama, Tawanda Pesanayi, Jeton Shatri, Mary Chamberlin, Ilir Hoxha
Summary: The evidence suggests that lifestyle factors such as alcohol and coffee intake may increase the risk of lung cancer, while tea intake may have a protective effect. However, the quality of evidence is currently low and further research is needed.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary Chamberlin, Christopher Booth, Gabriel A. Brooks, Achille Manirakiza, Fidel Rubagumya, Verna Vanderpuye
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Anne Christine Buteau, Alicia Castelo-Loureiro, Regina Barragan-Carrillo, Suyapa Bejarano, Alba J. Kihn-Alarcon, Enrique Soto-Perez-de-Celis
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Ilir Hoxha, Fitim Sadiku, Lot Hoxha, Midhet Nasim, Marie Anne Christine Buteau, Krenare Grezda, Mary D. Chamberlin
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
